記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#5-69E. Redefining Remission: Obinutuzumab Superiority in Primary Membranous Nephropathy (NEJM, 2026)
2026年9月18日 12:00·5分29秒
How can clinicians achieve durable remission in primary membranous nephropathy without relying solely on chronic calcineurin inhibition? The randomized phase 3 MAJESTY trial revealed that obinutuzumab was markedly superior to tacrolimus, delivering a 104-week complete remission rate of 37% versus 6%. Although its open-label design and two-year follow-up mandate caution regarding long-term renal protection, these findings establish obinutuzumab as a transformative therapy that could reshape clinical algorithms for achieving deep immunologic control.
Citation: Fervenza FC, Hou FF, Hao CM, Kirsztajn GM, Gesualdo L, Hryszko T, et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2602678
URL: https://doi.org/10.1056/NEJMoa2602678
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
コメントを投稿するにはログインが必要です
ログインページへ
